Glycoprotein (GP) of Ebola Virus (EBOV)

EBOV is an RNA virus. It contains a glycoprotein, GP. GP is involved in viral invasion and adsorption. As the predominant structural protein, GP appears as a trimer on the viral surface. Its monomeric structure is subdivided into GP1 and GP2. GP1 contains binding sites for host cell receptors. GP2 has a hydrophobic region at the C-terminal end and forms a transmembrane structural domain. Based on the antigenic mode of immunity, EBOV vaccines can be classified into three categories, including non-replicating expression vector-based vaccines, replicating viral vector-based vaccines, and viral protein antigen-based vaccines. GP is the most important protein mediating viral adsorption internalization and membrane fusion. Its surface contains key antigenic epitopes for inducing neutralization activity. Therefore, GP is ideal for vaccine studies.

EBOV Vaccine Development Service at CD BioGlyco

CD BioGlyco provides all experimental services for sugar-related Vaccine Development. The increasing maturity of exogenous gene expression technology has made Recombinant Subunit Vaccines a major development direction for novel vaccines. We provide recombinant subunit vaccine development services for EBOV.

GP is the only surface protein on the virus particle that regulates adsorption and fusion with host cells. Therefore, GP has become the main target protein for vaccine research. In order to increase the stability, solubility, and immunogenicity of the protein itself, we modify the GP, which has a complex structure and surface glycosylation. The complex structure and surface glycosylation of GP can be maximized by eukaryotic expression systems to restore the modifications and advanced structure of the viral proteins. We have a variety of eukaryotic expression systems to express recombinant GP. Afterward, we use optimized methods for purification and identification. Using mice as a model, the immunogenicity, and safety of the purified protein will be evaluated.

Vaccine adjuvants, defined by their function rather than the substance itself, have the function of enhancing the body's response to immunization against antigens. Co-immunization of recombinant subunit vaccines with adjuvants achieves the desired immunostimulatory effect. We also offer Adjuvant research services.

Fig.1 Experimental procedures for EBOV vaccine development. (CD BioGlyco)

Applications

• It is shown that recombinant protein vaccines can induce the production of containment-neutralizing antibodies. Our EBOV vaccine development service includes the production of recombinant GP, which can facilitate antibody development.
• Different types of vaccines may work better in combination. The EBOV vaccine we developed is also used to study the immunization effects of combining it with other vaccines.

Highlights

• We are skilled in recombinant gene technology. This technology allows the cloning of genes from pathogen antigens into prokaryotic or eukaryotic cells for direct production of the desired antigenic proteins. It avoids the harmful substances and genetic contamination of pathogens that remain in the purification process of traditional pathogen antigens and solves the safety problem from the source.
• We have a variety of eukaryotic expression systems to express recombinant GP, including the Mammalian transient expression system, Plant expression system, Yeast expression system, and so on.
• We provide a one-stop service for vaccine development, including antigen screening, antigen expression, antibody production, evaluation of immune effect, etc. The experimental cycle is short and efficient.

CD BioGlyco is experienced in sugar-related vaccine development and we aim to help to develop vaccines quickly and shorten the development cycle. In addition to EBOV vaccines, we also offer development services for HIV Vaccines, Influenza A Virus Vaccines, and more. If you are interested in our sugar-related vaccine development platform, please feel free to contact us to get more information.

Reference

1. Agnolon, V.; et al. Designs and characterization of subunit Ebola GP vaccine candidates: implications for immunogenicity. Front Immunol. 2020, 11: 586595.